AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells.

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

The ability to analyze gene expression at the single-cell level—known as single-cell RNA sequencing (scRNA-seq)—has ...

A new study, published recently in Nature Communications, offers the first-ever map of which parts of Chikungunya virus ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

AbbVie (ABBV) on Monday announced that it has entered into a definitive agreement to acquire privately held clinical-stage ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Studies undertaken by researchers at Queen Mary and University of Konstanz have identified a critical chemical signal in the ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type 1 diabetes, hepatitis ...

LJI scientists have discovered that T cells may help detect Parkinson's disease years before motor symptoms appear. Your T ...

A new study, published recently in Nature Communications , offers the first-ever map of which parts of Chikungunya virus trigger the ...

At first glance, some people seem to have recovered from COVID-19. They no longer test positive and can return to work or ...